PAMA Price Cuts Now Delivering One-Two Punch to Labs’ Revenue

First punch is less revenue from Medicare; Second punch are Medicaid lab test price cuts

WHEN DISCUSSING THEIR EARNINGS with Wall Street analysts in February, executives from both Laboratory Corporation of America (LabCorp) and Quest Diagnostics explained that the lab test price cuts from the Protecting Access to Medicare Act of 2014 (PAMA) were not only reducing revenue, but that many state Medicaid plans are following Medicare’s lead and cutting their …

PAMA Price Cuts Now Delivering One-Two Punch to Labs’ Revenue Read More »

To access this post, you must purchase The Dark Report.

The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103 • Toll Free Number: 800-560-6363
Email: customerservice@darkintelligencegroup.com

PAMA Price Cuts Now Delivering One-Two Punch to Labs’ Revenue

First punch is less revenue from Medicare; Second punch are Medicaid lab test price cuts

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month